Evidence map›Paper›PMID 20835842›Full record

ArticleCellular and molecular life sciences : CMLS2011

Kinetic and structural evidence of the alkenal/one reductase specificity of human ζ-crystallin.

Sergio Porté, Agrin Moeini, Irene Reche, Naeem Shafqat, Udo Oppermann, Jaume Farrés, Xavier Parés

Open access · greenAbstract read
In one paragraph

Article in Cellular and molecular life sciences : CMLS, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Zeta-crystallin: a moonlighting player in cancer.Cellular and molecular life sciences : CMLS · 2020
    Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Sergio PortéDepartment of Biochemistry and Molecular Biology, Faculty of Biosciences, Universitat Autònoma de Barcelona, Bellaterra, Spain.
Agrin Moeini
Irene Reche
Naeem Shafqat
Udo Oppermann
Jaume Farrés
Xavier Parés
Universitat Autònoma de Barcelona · ESGenomics (United Kingdom) · GBUniversity of Oxford · GB

Funding

CIHRWellcome Trust
6 · The paper itself

Abstract

Human ζ-crystallin is a Zn(2+)-lacking medium-chain dehydrogenase/reductase (MDR) included in the quinone oxidoreductase (QOR) family because of its activity with quinones. In the present work a novel enzymatic activity was characterized: the double bond α,β-hydrogenation of medium-chain 2-alkenals and 3-alkenones. The enzyme is especially active with lipid peroxidation products such as 4-hydroxyhexenal, and a role in their detoxification is discussed. This specificity is novel in the QOR family, and it is similar to that described in the distantly related alkenal/one reductase family. Moreover, we report the X-ray structure of ζ-crystallin, which represents the first structure solved for a tetrameric Zn(2+)-lacking MDR, and which allowed the identification of the active-site lining residues. Docking simulations suggest a role for Tyr53 and Tyr59 in catalysis. The kinetics of Tyr53Phe and Tyr59Phe mutants support the implication of Tyr53 in binding/catalysis of alkenal/one substrates, while Tyr59 is involved in the recognition of 4-OH-alkenals.

Indexed as

Models, MolecularAldehydesCatalysisCloning, MolecularCrystallography, X-RayDNA PrimersGas Chromatography-Mass SpectrometryHumansHydrogenationKineticsMolecular StructureMutagenesis, Site-DirectedProtein BindingProtein ConformationSubstrate Specificityzeta-Crystallins4-hydroxyhexenalAldehydesDNA Primerszeta-Crystallins

Identifiers

PMID20835842
PMCPMC11114546
OpenAlexW2028769071

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.